OCC
vs
S
S&P/ASX 300
OCC
Over the past 12 months, OCC has underperformed S&P/ASX 300, delivering a return of -44% compared to the S&P/ASX 300's +5% growth.
Stocks Performance
OCC vs S&P/ASX 300
Performance Gap
OCC vs S&P/ASX 300
Performance By Year
OCC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Orthocell Ltd
Glance View
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
